Ascendis Pharma A/S (NASDAQ:ASND) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Ascendis Pharma A/S (NASDAQ:ASND) has been assigned a consensus recommendation of “Moderate Buy” from the thirteen analysts that are presently covering the company, MarketBeat reports. One equities research analyst has rated the stock with a hold rating and twelve have assigned a buy rating to the company. The average 1-year target price among brokers that have issued ratings on the stock in the last year is $191.77.

Several research analysts have issued reports on ASND shares. JPMorgan Chase & Co. lowered their price target on shares of Ascendis Pharma A/S from $180.00 to $174.00 and set an “overweight” rating for the company in a report on Wednesday, October 23rd. Citigroup raised their price objective on shares of Ascendis Pharma A/S from $178.00 to $207.00 and gave the company a “buy” rating in a research note on Tuesday, September 17th. The Goldman Sachs Group upped their price target on Ascendis Pharma A/S from $180.00 to $200.00 and gave the stock a “buy” rating in a report on Tuesday, September 17th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $170.00 price objective on shares of Ascendis Pharma A/S in a research note on Friday, November 15th. Finally, Jefferies Financial Group raised their price target on shares of Ascendis Pharma A/S from $174.00 to $196.00 and gave the stock a “buy” rating in a research note on Tuesday, August 13th.

Institutional Trading of Ascendis Pharma A/S

Several institutional investors and hedge funds have recently modified their holdings of the stock. Frazier Life Sciences Management L.P. acquired a new position in Ascendis Pharma A/S during the 3rd quarter valued at about $19,908,000. Public Employees Retirement System of Ohio acquired a new position in shares of Ascendis Pharma A/S in the 3rd quarter valued at $1,101,000. Groupama Asset Managment purchased a new stake in shares of Ascendis Pharma A/S in the third quarter valued at approximately $60,000. Nomura Asset Management Co. Ltd. increased its holdings in Ascendis Pharma A/S by 42.5% in the 3rd quarter. Nomura Asset Management Co. Ltd. now owns 18,000 shares of the biotechnology company’s stock worth $2,688,000 after acquiring an additional 5,371 shares in the last quarter. Finally, Y Intercept Hong Kong Ltd purchased a new stake in shares of Ascendis Pharma A/S during the third quarter worth about $886,000.

Ascendis Pharma A/S Stock Performance

ASND opened at $129.81 on Wednesday. The firm has a market cap of $7.87 billion, a PE ratio of -16.07 and a beta of 0.66. The firm’s fifty day moving average is $133.22 and its two-hundred day moving average is $132.19. Ascendis Pharma A/S has a twelve month low of $90.13 and a twelve month high of $161.00.

Ascendis Pharma A/S (NASDAQ:ASND) last issued its quarterly earnings data on Tuesday, September 3rd. The biotechnology company reported ($2.05) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.54) by ($0.51). The business had revenue of $38.75 million for the quarter, compared to analysts’ expectations of $94.74 million. Equities analysts forecast that Ascendis Pharma A/S will post -7.45 EPS for the current fiscal year.

About Ascendis Pharma A/S

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.